I think they have a very solid product, present in 30 countries and 8 jurisdictions. I saw this kind of performance with Novo Nordisk and I think OncoSil has a similar profile. Innovation + strong management/commercial strategy does it for me. It's going to become the new pancreatic cancer medication used everywhere. I see the current market consolidation phase as a buying strategy.
I think they have a very solid product, present in 30 countries...
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.66M | |||
| Open | High | Low | Value | Volume |
| 0.6¢ | 0.6¢ | 0.5¢ | $4.47K | 886.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 6296690 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 22890532 | 25 |
View Market Depth
| Last trade - 14.42pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
0.5¢ |
Change
0.000 ( 11.1 %) |
||||
| Open | High | Low | Volume | ||
| 0.5¢ | 0.5¢ | 0.5¢ | 2050000 | ||
| Last updated 14.42pm 14/06/2024 ? | |||||
| OSL (ASX) Chart |